NobleBlocks

Research indexJournal article

Study

Hogan

Oncology Times1 Jul 2005

NobleIDark:/48914/w1/20260521/18FBB1BFDOI10.1097/01.cot.0000302900.23808.e8

Paywalled

The full text is at the publisher

You can read the abstract here, or open it at the publisher.

Read at the publisher

Abstract

The relative dearth of clinical trial participation by young adults with non-Kaposi sarcoma may partly explain their lack of survival improvement, according to a study led by Archie Bleyer, MD, Chair of Adolescent and Young Adult Oncology for the Children's Oncology Group (COG). “We believe the data should be interpreted to say that, because young adults with sarcomas, with the exception of Kaposi sarcoma, have not participated in clinical trials, they have not allowed us as a society to learn how to treat young adults with sarcomas, and, as a result, we've made little progress in prolonging lives,” Dr. Bleyer said in an interview. During the past quarter century, US cancer patients between the ages of 15 and 45 have had less survival prolongation and a lower mortality rate reduction than younger and older age groups, the researchers wrote. Sarcomas are particularly common among cancer patients in this age group. Previous studies done by Dr. Bleyer and his colleagues have shown the relationship between age and outcome improvement, measured by survival prolongation and mortality rate reduction, in all invasive cancers analyzed as a whole, and in leukemia, brain tumors, breast cancer, non-Hodgkin's lymphomas, and Hodgkin's disease, analyzed separately. In addition, an Australian study of young adults and older adolescents with bone sarcomas indicated a relationship between survival and participation in clinical trials. In the new study, published in the May 1 issue of Cancer and supported by the NCI, Dr. Bleyer and his coauthors analyzed data from 38,144 young adults with sarcoma who were diagnosed between 1975 and 1998 and included in the NCI's Surveillance, Epidemiology, and End Results-Medicare linked database, computing the average annual percentage change in five-year survival. Also included was information on 3,242 patients who joined NCI-sponsored trials between 1997 and 2002. The results showed that for bone and soft-tissue sarcomas, including Kaposi sarcoma, survival improvement correlated with trial participation. For patients with bone and soft-tissue sarcomas other than Kaposi sarcoma, a limited increase in survival was related to low participation in clinical trials. For these patients, the least survival increase occurred in the 15- to 45-year age group. For all sarcoma trials sponsored by the NCI, the lowest participation rate occurred in patients between the ages of 20 and 44. In Kaposi sarcoma patients, on the other hand, a greater survival increase correlated with higher trial participation. For these patients, the highest increase in survival occurred in those between the ages of 30 and 44, while the highest trial participation rate occurred in patients 35 to 44. Armed with this knowledge, the medical community's next step should be to improve clinical trial participation by both increasing patients' knowledge of trials and offering the studies, Dr. Bleyer said. “For both of these steps, there are good examples,” he said, referring in part to COG and the Intergroup Consortium Against Sarcoma (ICAS). As explained by Karen H. Albritton, MD, Director of Adolescent and Young Adult Oncology at Dana-Farber Cancer Institute, the consortium is made up of members of all the individual cooperative groups with the intent of combining intellectual forces, resources, and patient accrual. “Sarcoma is such a rare tumor that within each of the individual groups it was an underdog,” Dr. Albritton noted. “These groups struggled to get enough interest and accrual to survive.” The consortium provides trials for young adults through this cooperation, and COG has raised the upper age limit for enrollment in its trials, so they now include more adults.Figure: Archie Bleyer, MD (speaking at this year's ASCO Annual Meeting) found that for bone and soft-tissue sarcomas, including KS, survival improvement correlated with participation in a clinical trial.“The fact that the most recent year, 2003, had the greatest accrual of non-Kaposi sarcomas since 1997 may be the first sign of success of the COG and ICAS initiatives,” Dr. Bleyer and his colleagues wrote.

Discussion

Topics

More

Suggest a correction or report